Immunostaining for the proliferation marker Ki67 revealed that, compared to vehicle treated tumors, BEZ235 single treatment resulted in significant reduction of PC3 and PC3-AR tumor proliferation (PC3, p<0.0001; PC3-AR, p=0.0007). This evidence concerns the gene MKI67 and neoplasm.